OKUR vs. MNOV, BHST, ASMB, ME, ORMP, IMUX, PEPG, PYXS, ALXO, and IMAB
Should you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include MediciNova (MNOV), BioHarvest Sciences (BHST), Assembly Biosciences (ASMB), 23andMe (ME), Oramed Pharmaceuticals (ORMP), Immunic (IMUX), PepGen (PEPG), Pyxis Oncology (PYXS), ALX Oncology (ALXO), and I-Mab (IMAB). These companies are all part of the "pharmaceutical preparations" industry.
OnKure Therapeutics vs.
MediciNova (NASDAQ:MNOV) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability, community ranking and media sentiment.
9.9% of MediciNova shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 14.9% of MediciNova shares are held by company insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
MediciNova received 205 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 48.39% of users gave MediciNova an outperform vote.
MediciNova's return on equity of -17.55% beat OnKure Therapeutics' return on equity.
MediciNova has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500.
In the previous week, MediciNova had 2 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for MediciNova and 0 mentions for OnKure Therapeutics. MediciNova's average media sentiment score of 0.00 equaled OnKure Therapeutics'average media sentiment score.
MediciNova currently has a consensus price target of $9.00, indicating a potential upside of 389.13%. OnKure Therapeutics has a consensus price target of $36.00, indicating a potential upside of 510.17%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than MediciNova.
MediciNova has higher revenue and earnings than OnKure Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
MediciNova and OnKure Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get OnKure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OnKure Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OKUR) was last updated on 1/22/2025 by MarketBeat.com Staff
